http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Khan, Ashraful Islam,Ali, Mohammad,Chowdhury, Fahima,Saha, Amit,Khan, Iqbal Ansary,Khan, Arifuzzaman,Akter, Afroza,Asaduzzaman, Muhammad,Islam, Md. Taufiqul,Kabir, Alamgir,You, Young Ae,Saha, Nirod Ch Elsevier Science 2017 Vaccine Vol.35 No.11
<▼1><P><B>Highlights</B></P><P>•<P>Few women received the OCV unknowingly while pregnant during a large vaccine trial.</P>•<P>There is limited data on the safety of OCVs in pregnancy.</P>•<P>We evaluated the effect of a killed OCV, Shanchol™, on pregnancy outcomes.</P>•<P>Study showed no evidence of exposure to Shanchol™ on adverse pregnancy outcomes.</P></P></▼1><▼2><P><B>Background</B></P><P>Pregnant women are vulnerable to complications of cholera. Killed oral cholera vaccines (OCV) are not recommended for pregnant women though there is no evidence of harmful effects during pregnancy. We evaluated the effect of a killed OCV, Shanchol™, on pregnancy outcomes during an effectiveness trial of the vaccine in urban Bangladesh.</P><P><B>Methodology</B></P><P>Individuals ⩾1 year were invited to participate in the trial, conducted in 2011 in Dhaka, Bangladesh. Pregnancy by history was an exclusion criterion and all women of reproductive age (15–49 years) were verbally questioned about pregnancy at enrollment and prior to vaccination. Out of 48,414 women of reproductive age 286 women received the OCV unknowingly while pregnant. Out of these, we could recruit 69 women defined as exposed to OCV. Accordingly, we selected 69 pregnant women randomly from those who did not take the OCV (non-exposed to OCV). We evaluated adverse pregnancy outcome (spontaneous miscarriages, still births, or congenital malformations) between those who were exposed to OCV and those who were not exposed to OCV.</P><P><B>Results</B></P><P>About 16% of pregnant women exposed to OCV had pregnancy loss, as compared to 12% of unvaccinated pregnant women (P = 0.38). One congenital anomaly was observed and occurred in women non-exposed to OCV group. Models that adjusted for baseline characteristics that were unbalanced between the exposed and non-exposed groups, revealed a no elevation of risk of adverse pregnancy outcomes in vaccinees versus non-vaccinees (Adj. OR (95% CI): 0.45 (0.11–1.88).</P><P><B>Conclusions</B></P><P>No excess of adverse fetal outcomes associated with receipt of OCV was observed in this study.</P><P>Trial registration: Clinical Trials.gov number NCT01339845.</P></▼2>
Md Abdus Shahid,Abdur Rahim,Mohammad Asaduzzaman Chowdhury,Mohammad Abul Kashem 경희대학교 융합한의과학연구소 2022 Oriental Pharmacy and Experimental Medicine Vol.22 No.2
Nigella sativa (N. sativa) is extensively used as medicinal plant all over the world. It has the potential properties as the antiviral and antibacterial application. Its seed contain thymoquinone (TQ), thymohydroquinone (THQ), thymol (THY), p-cymene as major and other minor components. TQ and THQ exhibit broad spectrum of antimicrobial properties against the activity of bacteria, viruses, parasites, schistosoma and fungi. This work provides credence to the fabrication of antibacterial nanofibrous membrane by electrospinning machine from N. sativa extract with polyvinyl alcohol (PVA) solution for wound dressing. The morphology of the developed membrane is also characterized using scanning electron microscope. Fourier transform infrared spectroscopy (FTIR) data has been showed that the functional groups of N. sativa are present in the prepared PVA-N. sativa nanofibrous membrane and its antibacterial activity was investigated. The disk diffusion method has been used to evaluate the antibacterial activity of PVA-N. sativa nanofibrous membrane against Staphylococcus aureus (S. aureus) bacteria and the inhibition zone with a value of 10 mm is formed. Considering the inherent properties of N. sativa, a conceptual reaction mechanism has been proposed to deactivate the viral proteins by the action of TQ and THQ.